NAVIG-1 Vaccine

N/A

Report date: 2026/04/20 20:01:59

First In Class

Base Information

Drug NameNAVIG-1 Vaccine

Drug Alias NameA52-Mel/A49-Mel/Li28

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Polypeptide vaccineVaccines > Vaccine type > Multivalent vaccine

Mechanisms of ActionToll like receptor 9 agonists

TargetsReceptor-type tyrosine-protein phosphatase zetaTelomerase reverse transcriptaseToll like receptor 9

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAssistance Publique - Hôpitaux De Paris, France Altevax Bioscience

China Registration ClassN/A

Develop Information

Active CompaniesAltevax Bioscience

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A